NCT01666704View on ClinicalTrials.gov

Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

May 31, 2016

Conditions
Atherosclerotic Cardiovascular Disease
Interventions
DRUG

BMS-823778

Capsules, Oral, 2mg, Once daily, 1 year

DRUG

BMS-823778

Capsules, Oral, 15mg, Once daily, 1 year

DRUG

Placebo matching with BMS-823778

Capsules, Oral, 0mg, Once daily, 1 year

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01666704 - Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis | Biotech Hunter | Biotech Hunter